Regional Medical Scientific Director - West
Boost your chances before you apply.
Geron Corporation
CA
Summary
The Regional Medical Scientific Director builds scientific relationships with healthcare professionals to enhance medical education and support patient access to medicine. They serve as a subject matter expert on imetelstat and collaborate with internal teams to inform medical strategy and support clinical trials.
Job Description
Position Summary
The Regional Medical Scientific Director serves as a trusted partner for internal stakeholders and the healthcare community engaging in scientific exchange and relevant dialogue to enhance medical education, generate data and insights, and support patient access to medicine. The position will be based in California, while covering a territory of California, Nevada, Hawaii, and Arizona.
This position is remote with a corporate headquarters in Foster City, CA and Parsippany, NJ and will report to the Senior Director, National Field Medical Team.
Primary Responsibilities
- Identifies, develops, and maintains peer-to-peer scientific relationships with Healthcare Professionals (HCPs) in lower risk MDS, MF, and AML; connects with HCPs in academic and community centers as per the Medical Affairs plan and goals
- Serves as a scientific resource to external HCPs and internal stakeholders by staying up-to-date on latest training materials, scientific and clinical literature, evolving competitive landscape, and any other relevant information necessary to remain a subject matter expert
- Collaborates across multiple functions and within a region to maximize territory opportunities
- Provides fair and balanced scientific information and education to HCPs on published imetelstat data, disease management, treatment landscapes, mechanisms of action, and molecular pathways, in accordance with Company directives
- Partners with research and development functional groups to support Company-sponsored clinical trial enrollment and imetelstat lifecycle management
- Act as a primary liaison to investigators interested in developing and performing investigator-sponsored research
- Collaborates with physicians on Medical Affairs initiatives, including publications, medical education opportunities, training, and speaker development
- Communicates clinical insights to internal cross-functional partners to inform medical strategy
- Trains internal stakeholders and field partners on key scientific and medical topics, as appropriate
- Maintains effective and appropriate communication among internal stakeholders while ensuring full compliance with relevant requirements
- Generates compliant territory plans to provide needs-based, value-added support of the medical and scientific community in line with Company goals
- Maintains timely and accurate reporting and documentation of all activities with HCPs
- Travel domestically and internationally approximately up to 75% of the time
Competencies
- Detailed knowledge of clinical medicine, disease management, patient treatment trends, national/regional healthcare and access environment, clinical trial design, and competitive landscape in malignant hematology/oncology
- Proven ability to work independently as well as in cross-functional networks in a high growth, fast-paced environment
- Current knowledge of scientific and treatment landscape trends in malignant hematology
- Excellent communication, presentation, and time management skills
- Strong interpersonal skills and ability to establish, maintain, and grow professional relationships
- Possess a thorough understanding of US legal, regulatory, and compliance regulations and guidelines relevant to industry interactions with external and internal partners
- Demonstrated knowledge of CRM tools, Microsoft Office products, and virtual engagement platforms
Experience
- MD, PharmD, DNP, PhD; advanced or doctoral degree in scientific discipline with substantial and relevant pharmaceutical or biotechnology experience
- At least 5 years in US Field Medical, Medical Affairs, or related industry roles
- Clinical experience in hematologic malignancies, preferred
- Professional licensure, certifications, and credentials must be active, in good standing, and maintained
- Valid Driver’s license and satisfactory MVR record
- Must meet all credentialing requirements for access to academic institutions, medical facilities, and organizations that are in the assigned geography; these credentialing requirements may include, but are not limited to, background checks, drug screens, and proof of immunization and/or vaccinations
EEO Statement:
All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or protected veteran status.
Benefit Statement:
All regular-status, full-time employees of Geron are eligible to participate in the Company’s comprehensive benefit program, pursuant to plan terms and conditions. Plan choices include medical, dental, vision, life insurance, flexible spending accounts, disability insurance, supplemental health insurance, a 401(k) retirement savings plan, and an employee stock purchase plan. Geron also provides regular-status, full-time employees with a generous time off program that includes the eligibility to accrue 160 hours of vacation during each full year of employment, 64 hours of sick leave, 9 standard paid holiday days off, and paid leave for certain life events. Geron recognizes that its employees work in many different states and therefore may be affected by different laws. It is Geron’s intention to comply with all applicable federal, state, and local laws that apply to the Company’s employees.
Salary Statement:
Offered compensation is determined based on market data, internal equity, and an applicant’s relevant skills, experience, and educational background.
General Salary Range: $230,000 to $245,000
al Science Liaison
Geron is a biopharmaceutical company that is charting a new course with the goal to deliver innovative treatment options for people living with blood cancer. Our tireless pursuit to improve outcomes for these patients resulted in the U.S. approval of the first ever telomerase inhibitor for the treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia.
As the sole company with an oligonucleotide telomerase inhibitor approved by the FDA, we feel a deep urgency to bring the potential power of telomerase inhibition to patients in need. We are conducting research in other blood cancers with high unmet need beyond LR-MDS, with ongoing clinical trials across other hematologic malignancies, including a pivotal Phase 3 clinical trial in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF).
We are proud of the impact this Nobel-winning science is having in the fight against blood cancers. At Geron, we are united by a shared purpose: Every individual in every role can meaningfully contribute to our mission to change lives by changing the course of blood cancer. With a culture rooted in courage and determination, we will continue to innovate and pursue new possibilities for patients.
To learn more, visit www.geron.com.
Geron’s Community Guidelines: https://www.geron.com/CommunityGuidelines/
Founded
1992
Company size
201-500 employees
Industry
Biotechnology Research
Org type
Public Company
Headquarters
Foster City, California
Geron is a biopharmaceutical company that is charting a new course with the goal to deliver innovative treatment options for people living with blood cancer. Our tireless pursuit to improve outcomes for these patients resulted in the U.S. approval of the first ever telomerase inhibitor for the treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia.
As the sole company with an oligonucleotide telomerase inhibitor approved by the FDA, we feel a deep urgency to bring the potential power of telomerase inhibition to patients in need. We are conducting research in other blood cancers with high unmet need beyond LR-MDS, with ongoing clinical trials across other hematologic malignancies, including a pivotal Phase 3 clinical trial in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF).
We are proud of the impact this Nobel-winning science is having in the fight against blood cancers. At Geron, we are united by a shared purpose: Every individual in every role can meaningfully contribute to our mission to change lives by changing the course of blood cancer. With a culture rooted in courage and determination, we will continue to innovate and pursue new possibilities for patients.
To learn more, visit www.geron.com.
Geron’s Community Guidelines: https://www.geron.com/CommunityGuidelines/
Founded
1992
Company size
201-500 employees
Industry
Biotechnology Research
Org type
Public Company
Headquarters
Foster City, California